Bronte Capital Management Pty Ltd. Buys 139,810 Shares of Bath & Body Works, Inc. $BBWI

Bronte Capital Management Pty Ltd. lifted its holdings in Bath & Body Works, Inc. (NYSE:BBWI) by 121.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 254,611 shares of the company’s stock after purchasing an additional 139,810 shares during the period. Bath & Body Works accounts for approximately 0.6% of Bronte Capital Management Pty Ltd.’s portfolio, making the stock its 22nd biggest holding. Bronte Capital Management Pty Ltd.’s holdings in Bath & Body Works were worth $5,113,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in BBWI. Royal Bank of Canada increased its stake in shares of Bath & Body Works by 92.8% in the first quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock worth $1,815,000 after purchasing an additional 28,815 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Bath & Body Works by 15.7% in the first quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock worth $19,586,000 after purchasing an additional 87,529 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Bath & Body Works by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock worth $17,063,000 after purchasing an additional 36,684 shares during the period. Intech Investment Management LLC bought a new position in shares of Bath & Body Works in the first quarter worth about $1,155,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after purchasing an additional 801 shares during the period. 95.14% of the stock is currently owned by institutional investors.

Bath & Body Works Stock Down 1.0%

Shares of BBWI opened at $18.38 on Wednesday. Bath & Body Works, Inc. has a 12-month low of $14.27 and a 12-month high of $34.66. The firm has a market capitalization of $3.70 billion, a price-to-earnings ratio of 5.84, a P/E/G ratio of 1.86 and a beta of 1.43. The stock’s 50-day moving average price is $19.77 and its 200 day moving average price is $21.05.

Bath & Body Works (NYSE:BBWI) last issued its quarterly earnings results on Wednesday, March 4th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.28. Bath & Body Works had a negative return on equity of 45.60% and a net margin of 8.90%.The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.59 billion. During the same period in the previous year, the company posted $2.09 earnings per share. The company’s quarterly revenue was down 2.3% compared to the same quarter last year. Bath & Body Works has set its Q1 2026 guidance at 0.240-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. Equities research analysts expect that Bath & Body Works, Inc. will post 2.6 EPS for the current year.

Bath & Body Works Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, February 20th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.4%. The ex-dividend date was Friday, February 20th. Bath & Body Works’s payout ratio is currently 25.40%.

Wall Street Analyst Weigh In

BBWI has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft lifted their price objective on Bath & Body Works from $21.00 to $22.00 and gave the stock a “hold” rating in a research note on Tuesday, March 3rd. Telsey Advisory Group lifted their price objective on Bath & Body Works from $23.00 to $25.00 and gave the stock a “market perform” rating in a research note on Thursday, March 5th. Jefferies Financial Group initiated coverage on Bath & Body Works in a research note on Wednesday, January 14th. They issued a “hold” rating and a $24.00 price objective on the stock. Citigroup lowered Bath & Body Works from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $21.00 to $25.00 in a research note on Tuesday, February 17th. Finally, Zacks Research upgraded Bath & Body Works from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 20th. Three investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $23.00.

About Bath & Body Works

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.